
Lilly expands infectious-disease portfolio with three-broker vaccine acquisitions
Eli Lilly is buying Curevo, LimmaTech Biologics, and Vaccine Company for up to $3.8 billion in upfront and milestone payments to broaden its infectious-disease pipeline. Curevo brings a shingles vaccine candidate, LimmaTech adds a Staphylococcus aureus vaccine program, and Vaccine Company offers vaccines targeting flaviviruses and an EBV-focused program, signaling Lilly’s shift toward preventative vaccines and a strategy to build a diversified vaccine portfolio alongside its strong oncology and metabolic franchises.












